Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg Ulcers

: The clinical investigation is a non-comparative, one-armed, open-labelled, multi-centre study

The test product, Biatain Fiber Ag is a non-CE-marked gelling fiber wound dressing, containing silver. The product is intended for moist wound healing and exudate management of moderate to high exuding wounds.

The overall purpose of this investigation is to obtain clinical data supporting effectiveness of Biatain Fiber Ag to obtain the CE-mark in EU.

The total study duration for the subject will be approximately four weeks, consisting of a four-week test period and 6 study visits (V0/V1, V2, V3, V4 and V5). V5 will also terminate the 4-week study period.

The primary endpoint is Mean area wound reduction. The endpoint is used to evaluate clinical performance in terms of relative wound area reduction as an indication of total wound healing.

Inclusion criteria

• Has signed informed consent
• Is 18 years or above
• Is capable of following study procedure (assessed by the investigator).
• Has a venous leg ulcer that has failed to progress along the expected wound healing trajectory within 4 weeks
• The shape of the wound should be possible to fit under a 10x10 cm dressing
• The shape and location of the wound should be suitable for photo capture (assessed by the investigator).
• Has at least three of five pre-defined clinical signs of infection; pain between two dressing changes, peri-ulcer skin erythema/inflammation, oedema, malodour, or heavy exudate (assessed by the investigator).
• Has a wound that has medium to high level of exudate (assessed by the investigator).
• Has an ankle to brachial pressure index (ABPI) of 0.8 -1.3
• Agrees to wear compression therapy daily in combination with the test dressing
• Is suitable to use the test product for wound treatment (assessed by the investigator).

Exclusion criteria

• Is pregnant/breastfeeding
• Wound is older than 12 months
• Wound with exposed tendons or bones or has fistulas
• Wound which is undermined or tunneling
• Is currently receiving or has within the past 60 days received radio- and/or chemotherapy (low doses radio- and/or chemotherapy is allowed for other indications than cancer if assessed by investigator not to influence study wound area)
• Known history of skin sensitivity to any components of the treatment dressings
• Intake of antibiotics within one week before the start of the enrolment
• Participation in any other clinical studies that can compromise this study treatment (assessed by the investigator).